U.S. stock market abnormality | Kardigan (KARD.US) debuts on the U.S. stock market and opens more than 25% higher.

According to Zhtng Finance APP, on Thursday, Kardigan (KARD.US) debuted on the US stock market, with its opening stock price rising by over 25% to $20.1. The IPO price was $16. Kardigan is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular diseases, dedicated to developing a new generation of precision drugs for treating arrhythmias and other heart diseases. The company's core product pipeline focuses on regulating cardiac electrophysiological function, improving abnormal rhythm problems by targeting specific ion channels, with the goal of increasing efficacy while reducing the safety risks associated with traditional antiarrhythmic drugs. Currently, the company's multiple candidate drugs are still in the clinical development stage and have not yet generated commercial revenue.